Interim data from INSPIRE study of Alofisel shows clinical remission rate in Crohn’s disease – Takeda
Takeda announced the first six-month interim analysis results from INSPIRE, in which clinical remission was observed in 65% of patients in both cohorts who were evaluated at 6… read more.